Skip to content
health about

What Clinical Trial Phases Mean: Phase 1, 2, 3 and 4

News about a new drug often names a trial phase. Here is what Phase 1, 2, 3 and 4 trials test, how many people they usually involve according to the FDA, and why an early-phase result is not yet an answer.

By health about Editorial Team · Last updated Sep 24, 2026 · 3 min read

A hand holding a newspaper beside a warm cup of coffee
Photo: Anna Keibalo / Unsplash
On this page
  1. Before any phase: the plan
  2. The phases at a glance
  3. What each phase tells you
  4. Why early results are not the final word
  5. Thinking about joining a trial

Key takeaways

  • Phase 1 tests safety and dosage in a small group of people.
  • Phase 2 looks for early signs of effectiveness and more safety data.
  • Phase 3 tests whether a treatment offers a benefit in hundreds to thousands of people.
  • Phase 4 monitors a treatment after approval.
  • An early-phase result is a step in the process, not proof that a treatment works.

Before a new drug can be approved, it usually goes through a series of clinical trials in people, from small early studies to large late-stage ones [1]. Knowing the phases helps you read a headline about a "promising" treatment.

Before any phase: the planLink to section: Before any phase: the plan

Every trial follows a study plan, called a protocol, that sets out who can take part, how many people will join, whether there will be a control group and other ways to limit bias, how the drug will be given and what will be measured [1]. Before a trial starts, scientists run laboratory tests and often animal studies, and the FDA must allow the drug to be tested in people [2].

The phases at a glanceLink to section: The phases at a glance

The FDA describes the phases like this [1]:

Phase Who takes part Typical length Main purpose
Phase 1 20 to 100 healthy volunteers or people with the condition Several months Safety and dosage
Phase 2 Up to several hundred people with the condition Several months to 2 years Effectiveness and side effects
Phase 3 300 to 3,000 people with the condition 1 to 4 years Effectiveness and monitoring of side effects
Phase 4 Several thousand people with the condition After approval Safety and effectiveness in wider use

What each phase tells youLink to section: What each phase tells you

Phase 1 gathers information about how a drug interacts with the body, how much of it people can tolerate and what its short-term side effects are [1].

Phase 2 gives the drug to people with the condition it is meant to treat. The FDA notes these studies are usually not large enough to show whether the drug will be beneficial; they provide more safety data and help design Phase 3 [1].

Phase 3 studies, sometimes called pivotal studies, are designed to show whether a treatment offers a benefit to a specific group of people [1]. Because they are larger and longer, they are more likely to show long-term or rare side effects [1]. The NIA adds that Phase 3 often compares the new treatment with other drugs or treatment approaches [2].

Phase 4 happens after FDA approval, monitoring effectiveness and safety in large, diverse groups [2]. Some side effects may not become clear until more people have used a treatment over a longer time [2].

Why early results are not the final wordLink to section: Why early results are not the final word

Many drugs stop along the way. The FDA estimates that about 70% of drugs move from Phase 1 to the next phase, and about 33% move on from Phase 2 [1]. So a headline about an encouraging Phase 1 or Phase 2 result describes an early step, not an approved treatment.

When you read about a trial, it also helps to check whether it was "blinded," so that neither the participants nor the researchers knew who got which treatment, since knowing can affect people's impression of whether someone improved [3]. For more questions to ask about a study, read how to read a health news story.

Thinking about joining a trialLink to section: Thinking about joining a trial

Joining a trial is a personal decision with possible benefits and some risks [2]. The NIA suggests asking the research team what the study is trying to find out, what the possible risks and benefits are compared with your current treatment, how long it will last and how it will affect your everyday life [2]. Let your own health care provider know if you are considering a trial [2].